Search tips
Search criteria 


Logo of scirepAboutEditorial BoardFor AuthorsScientific Reports
Sci Rep. 2016; 6: 28993.
Published online 2016 July 4. doi:  10.1038/srep28993
PMCID: PMC4931578

Differential expression of microRNAs in retinal vasculopathy caused by selective Müller cell disruption


Vascular changes and photoreceptor degeneration are features of age-related macular degeneration, diabetic retinopathy and macular telangiectasis. We have profiled the differential expression of microRNAs and analysed their target genes in transgenic mice in which induced Müller cell disruption results in photoreceptor degeneration, vascular leak and deep retinal neovascularisation. We identified 9 miRNAs which were differentially expressed during the development of retinal neovascularization and chose miR-200b and its target genes for further study. Using qRT-PCR and western blot analysis, we found that downregulation of miR-200b was negatively correlated with its target genes, including zinc finger E-box binding homeobox (ZEB) 1 and 2 and vascular endothelial growth factor receptor 1. Double immunofluorescence labelling revealed that the newly formed vessels in the outer retina were positive for ZEB2. Furthermore, intravitreal injections of a miR-200b-mimic and anti-miR-200b confirmed the negative correlation of miR-200b and its target gene expression. We also found that the miR-200b-mimic inhibited vascular leak in the established mild vascular lesions, whereas anti-miR-200b promoted it. Taken together, these data suggest that miR-200b may play a role in the development of intraretinal neovascularisation.

MicroRNAs (miRNAs) are small, non-coding RNA molecules, which regulate post-transcriptional gene expression by binding to complementary sites on the 3′ untranslated region (UTR) of target genes. miRNAs have been recognized as a major player in post-transcriptional regulation of gene expression1. A single miRNA can modulate a wide range of genes since a short complementary sequence site to 3′UTR is required and imperfect complementary binding can still modulate target gene expression1,2.

There is increasing evidence that miRNAs play important roles in cellular proliferation, differentiation and cell death and are involved in all aspects of the biological processes investigated thus far3. Recent studies have reported that miRNAs play a role in the development of vasculopathy, such as endothelial migration and proliferation, and tumour angiogenesis4. In addition to in vitro and in vivo laboratory evidence, clinical assessment of circulating miRNAs in patients with coronary artery disease has reported high levels of pro-angiogenic miRNAs in the blood5. There is increasing evidence that miRNAs are also implicated in the pathogenesis of retinal degeneration, blood retinal barrier breakdown and retinal angiogenesis6,7,8,9.

Retinal vascular diseases, such as diabetic retinopathy and retinal vein occlusion, are leading causes of blindness and are often accompanied by blood retinal barrier breakdown and ocular neovascularisation10,11. Although there are now a number of treatments available for retinal vascular diseases, including intravitreal injections of steroids and antibodies against vascular endothelial growth factor, laser photocoagulation and vitrectomy, these treatments also have limitations12,13,14,15. For example, it has been well documented that overexpression of vascular endothelial growth factor (VEGF) promotes blood retinal barrier breakdown and ocular neovascularization16,17, however, recent studies suggest that long-term delivery of anti-VEGF agents may have unexpected local and systemic adverse effects18,19,20,21,22,23. Therefore, the development of other ways to treat retinal vascular diseases is warranted.

Müller cells span the retina from the internal to the external limiting membranes. They ensheath blood vessels in the plexiform and nerve fiber layers as well as all retinal neurones. Müller cells are important for the maintenance of retinal homeostasis and are involved in regulation of the blood retinal barrier, thereby controlling retinal blood supply and angiogenesis24. In order to study the role of primary Müller cell dysfunction in retinal diseases, we have generated transgenic mice in which induced Müller cell disruption leads BRB breakdown and deep retinal neovascularisation as well as photoreceptor degeneration25. These changes are important features of retinal diseases such as diabetic retinopathy, retinal vein occlusion, macular telangiectasis type 2 and some forms of age-related macular degeneration26,27,28,29.

We have recently reported the profile of differential expression of miRNAs and their target genes during the phase of photoreceptor degeneration which peaks around 2 weeks after Müller cell disruption in this model30, identifying 20 miRNAs and 78 target genes31,32. Since intraretinal neovascularisation appears from 2 months and persists for at least another 3 months after the induced Müller cell disruption25, in this study we have profiled differential expression of miRNAs and their target genes, with particular attention to the contribution of miR-200b-3p to retinal vasculopathy, 3 months after Müller cell disruption.


miRNA profiling and target gene prediction

We firstly performed microRNA PCR array to profile differential expression of miRNAs 3 months after Müller cell disruption, at which time vascular leak and deep retinal neovascularisation are well established in this model. We identified 9 miRNAs, which were significantly differentially expressed. These included miR-133a-3p, miR-133b-3p, miR-146b-3p, miR-200a-3p, miR-200b-3p, miR-215-5p, miR-223-3p, miR-1936 and miR-202-3p (Fig. 1A and Table 1). Of these, miR-200 family members, including miR-200a-3p and miR-200b-3p, were significantly downregulated whereas all others were upregulated (Fig. 1A and Table 1). We next used two target gene prediction databases, TargetScan ( and miRTarbase (, to predict genes which could be potentially targeted by the 9 miRNAs. In silico analysis and a literature search-based functional analysis revealed which biological functions these differentially expressed miRNAs might be involved in (Table 1). Interestingly, these changes in the miR-200 family 3 months after Müller cell disruption were consistent with the findings reported by others in diabetic retinas7.

Figure 1
Differentially expressed miRNAs 3 months after Müller cell disruption and its target gene validation with qRT-PCR.
Table 1
List of differentially expressed miRNAs 3 months after Müller cell disruption.

We next focused on miR-200b-3p since previous studies had reported that it and its target genes play an important role in angiogenesis7,33,34. Analysis using target gene databases revealed that there were more than 500 genes that could be targeted by miR-200b-3p. Of these, we chose 3 genes, including zinc finger E-box binding homeobox 1 and 2 (ZEB1 and ZEB2), which had the highest matching scores in analysis using conserved seed matching sequence alignments (Table 2), and vascular endothelial growth factor receptor 1 (VEGFR1, also termed FLT1), for further validation by qRT-PCR and western blot.

Table 2
Seed matching sequence alignments between miR-200b and its target genes including ZEB1, ZEB2 and FLT1.

Target gene validation by qRT-PCR and Western blots

We performed qRT-PCR to study changes in ZEB1, ZEB2, FLT1 and VEGF-A expression 3 months after Müller cell disruption. The primer sequences are listed in Supplementary Table 1. We found that all 4 genes were upregulated (Fig. 1B). Of these, changes in ZEB1 and ZEB2 expression were statistically significant (p < 0.05, Fig. 1B).

Western blots for ZEB1, ZEB2, FLT1 and VEGF-A revealed alterations in protein expression, which were generally consistent with the qRT-PCR. Quantitative analysis of protein bands showed significant increases in ZEB2 and VEGF-A expression, while changes in ZEB1 and FLT1 were not statistically significantly different (Fig. 2).

Figure 2
Western blot analysis of proteins targeted by miR-200b after Müller cell disruption.

Immunofluorescence labelling

We further performed immunofluorescence studies to localise the expression of ZEB2 after selective Müller cell disruption. We chose ZEB2 since it showed the most significant changes in both qRT-PCR and western blot analysis. We conducted double immunofluorescence labelling using antibodies against ZEB2 in combination with an antibody against cellular retinaldehyde binding protein (CRALBP), which is a marker for Müller cells. We found that ZEB2 was mainly expressed in the ganglion cell layer (GCL), the inner nuclear layer (INL) and the outer plexiform layer (OPL) but was hardly detected in the outer retina of the normal retina (Fig. 3A–D). Selective Müller cell disruption resulted in increased immunoreactivity for ZEB2 in some cells of the outer retina where Müller cell disruption had resulted in defects of the outer limiting membrane (Fig. 3E–G, small arrows) through which cell bodies from the outer nuclear layer (ONL) protruded into the subretinal space (Fig. 3H, large arrows). Immunostaining for ionized calcium-binding adapter molecule 1 (Iba1), a marker of microglia, indicates that the protrusion of degenerate photoreceptors (Supplementary Fig. 1G,H, large arrows) was accompanied by infiltration of activated microglia in the outer retina (Supplementary Fig. 1G,H, small arrows).

Figure 3
Increased immunoreactivity for ZEB2 in the outer retina after induced Müller cell disruption.

We also performed double labelling using isolectin b4 (IB-4) for blood vessels together with ZEB2 to study the relationship between abnormal vessel growth and ZEB2 overexpression (Fig. 4). The normal retinal vasculature in control mice was decorated by ZEB2 antibodies in the INL and OPL of the superficial retina (Fig. 4A–F). However, the newly developed vessels which developed in patches of Müller cell disruption showed strong immunoreactivity for ZEB2, indicating a direct association between ZEB2 overexpression and the growth of abnormal vessels in the outer retina (Fig. 4G–L).

Figure 4
Double labelling for ZEB2 and isolectin B4 (IB-4) 3 months after Müller cell disruption.

In vivo gain and loss of function studies following intravitreal injections of miR-200b regulators

In order to verify the effect of miR-200b on retinal vasculopathy in vivo, we performed intravitreal injections of both a miR-200b-3p mimic and inhibitor 3 months after induced Müller cell disruption. Prior to the injection, we confirmed the development of vascular lesions by fundus fluorescein angiography (FFA). The effects of the miR-200b-3p mimic and inhibitor on established vascular lesions were evaluated by re-examination with FFA 7 days after their intravitreal injection.

We analysed changes in retinae with mild and severe vascular lesions following intravitreal injections (Fig. 5). In both groups, vascular leak remained relatively unchanged 1 week after injections of a scrambled miRNA (Fig. 5A,D,G,J). Inhibition of leak from mild vascular lesions was observed in eyes receiving the miRNA mimic (Fig. 5B,E) but this effect was not obvious in eyes, which had developed severe vascular lesions before the intravitreal injection (Fig. 5H,K). As expected, anti-miR targeting miR-200b-3p appeared to promote the development of mild vascular lesions (Fig. 5C,F). However, similar to the effect of miRNA-mimic on severe vascular lesions, intravitreal injection of anti-miR showed little effect on severe vasculopathy 1 week after injection (Fig. 5I,L).

Figure 5
The effects of intravitreal injections of miR-200b regulators on mild (AF) and severe (GL) vascular lesions. (AC,GI) Fundus fluorescein angiograms before intravitreal injections. (DF,JL) Fluorescein ...

In order to evaluate the effects of intravitreal injections of the miR-200b-3p mimic and inhibitor on its target protein expression, we performed western blots using retinas collected from eyes receiving scrambled miRNA, the mRNA-mimic and anti-miR (Fig. 6). Consistent with the negative correlation between miR-200b-3p and its target molecules, intravitreal injection of miR-200b-3p mimic significantly suppressed or tended to decrease the expression of ZEB2 (P < 0.05), VEGF-A and FLT1, whereas anti-miR-200b-3p significantly increased or tended to stimulate the expression of these target proteins compared with eyes receiving a scramble miRNA (Fig. 6). The negative correlations between miR-200b-3p and its target proteins were more obvious when comparisons were made between mimic- and anti-miR-injected retinas (p < 0.01, Fig. 6).

Figure 6
The impact of intravitreal injections of miR-200b mimic and anti-miR-200b on ZEB2, VEGF-A and FLT1 expression.


This study identified 9 miRNAs which were differentially expressed when intraretinal neovascularisation occurred in the model we used 3 months after induced Müller cell disruption. We used multiple target gene prediction databases to predict genes which could be potentially targeted by these 9 miRNAs. We have particularly focused on the involvement of miR-200b-3p in the development of deep retinal neavascularisation through target gene validation using qRT-PCR, western blot analysis and immunofluorescence in combination with in vivo gain and loss of function studies after intravitreal injections of miR-200b regulators.

It has been previously reported that miRNAs are involved in ocular neovascularization in oxygen-induced retinopathy35,36 and laser-induced choroidal neovascularization37. This work is the first study to indicate that differentially expressed miRNAs are involved in the development of deep intraretinal neovascularization caused by prolonged primary Müller cell dysfunction.

The miR-200 family is well known for its inhibitory effect on angiogenesis through modulating transcription of various target genes such as ZEB1, ZEB2, Ets-1, VEGF, thrombospondin-1, and vasohibin-27,34,38,39,40. Of this family, miR-200b is particularly important due to its involvement in the vascular complications of retinal diseases. ZEB2 has been reported to modulate tight junction and gap junction proteins, such as claudin 4, ZO-3, gap junction protein β2 and β341. Our previous study using microarray analysis revealed downregulation of tight junction-associated molecules 3 months after Müller cell disruption25,42, we found significant downregulation of miR-200a-3p and miR-200b-3p 3 months after Müller cell disruption in this study. In addition, we conducted in silico analysis to predict which genes might have been targets of miR-200b-3p. We chose ZEB1, ZEB2 and FLT1 for further study with qRT-PCR and western blot because these molecules had the highest seed matching scores in analysis by conserved seed matching sequence alignments. Changes in VEGF-A expression were also examined due to its role in promoting vascular leak and ocular neovascularisation. qRT-PCR and western blot analysis found a negative correlation between miR-200b-3p and its target genes, particularly ZEB2. This observation is consistent with previous reports that miR-200b supresses ZEB1 and ZEB2 expression and vice versa43,44,45,46,47. Double immunofluorescence labelling showed overexpression of ZEB2 in abnormal vessels growing into the outer retina after selective Müller cell disruption. This is the first report that upregulation of ZEB2 may be involved in pathological ocular angiogenesis. Collectively, our data indicate that differential expression of miR-200b and its target genes may contribute to the development of vasculopathy in retinal diseases.

We conducted gain and loss of function studies to examine the effects of intravitreal injections of miR-200b mimic and anti-miR-200b in transgenic mice that had developed vascular lesions after Müller cell disruption. For the eyes which had developed mild vascular lesions, the miR-200b mimic inhibited the established vascular leak whereas anti-miR-200b promoted vascular leak. Considering the negative correlation between miR-200b and VEGF expression, future studies are warranted to test whether prolonged expression of anti-miR-200b stimulates normal blood vessels to proliferate and whether miR-200b mimic causes retinal capillary atrophy.

This study also found that neither the miR-200b mimic nor anti-miR-200b had a significant effect on established severe vascular lesions. Despite this discrepancy, data from western blots confirmed that these miRNA regulators did have the predicted effects on target gene expression. Future studies using higher doses of miR-200b mimics and anti-miR-200b are warranted to provide a better understanding of the role of miR-200b in different stages of retinal vasculopathy. It is possible that the lack of effect of miR-200b regulators on more severe vasculopathy might reflect a wide spectrum of interactions between miRNAs and their target gene expression. For example, the biological functions of one gene can be regulated by multiple miRNAs and vice versa1,2. We also acknowledge that the miRNeasy Mini Kit we employed only screens selected 372 miRNAs. Therefore, there is a possibility that we could have missed out certain miRNAs which may also play a potential role in the development of retinal vasculopathy caused by selective Müller cell disruption.

In summary, we have profiled the differential expression of miRNAs in transgenic mice in which selective Müller cell disruption results in deep intraretinal neovascularisation. Our data indicate that miR-200b and its target gene ZEB2 may play an important role in the development of intraretinal neovascularisation caused by prolonged Müller cell dysfunction.

Materials and Methods


This study was performed in accordance with the Association for Research in Vision and Ophthalmology guidelines for animal research and was approved by the University of Sydney animal ethics committee. Rlbp1-CreER mice were crossed with Rosa-DTA176 mice to produce Rlbp-CreER-DTA176 transgenic mice as reported previously25. Müller cell disruption was induced by daily intraperitoneal injection of tamoxifen for 4 consecutive days at 8–10 weeks of age25. Wild type mice receiving TMX in the same way were used as controls. Fundus fluorescein angiography was performed periodically to monitor retinal vascular changes after Müller cell disruption as described previously25. Mice were euthanized 3 months after Müller cell disruption. Retinae were isolated, snap frozen in liquid nitrogen and stored at −80 °C until use. In addition, eyes were also fixed with 4% paraformaldehyde and embedded in Optimal Cutting Temperature compound.

MicroRNA profiling and target gene prediction

A miRNeasy Mini Kit (Qiagen, 217004) was used to extract miRNAs according to the manufacturer’s instructions. 1 μg of total RNA from each of 12 retinae (6 transgenic, 6 wild type) were reverse-transcribed with a miRNA specific reverse transcript kit, miScript II RT (Qiagen, 218160), and miRNA PCR array was performed with 384 well-plate miScript miRNA High Content PCR array (Qiagen, MIMM-3001Z) which contains miScript primers for 372 of the most well characterised miRNAs. The identities of 372 miRNAs are listed in Supplementary Table 2. The thermo-cycle of the PCR array were denaturing at 94 °C for 15 seconds, annealing at 55 °C for 20 seconds and extension at 70 °C for 30 seconds with a total of 40 cycles. Relative quantification was performed by the [increment][increment]CT method as recommended by the manufacturer ( A p-value < 0.05 was considered statistically significant and the fold change cut-off criterion was ±2.

Quantitative RT-PCR (qRT-PCR)

qRT-PCR was performed to validate target gene expression as previously described42. In brief, total RNA was extracted and cDNA synthesis was performed with a SuperScript VILO cDNA Synthesis kit (Life Technologies, 11754050). Diluted cDNA was used for PCR reaction with Express SYBR GreenER qPCR Supermix (Life Technologies, 11784-200) according to manufacturer’s instruction. The quantitative analysis was performed by Relative Expression Software Tool (REST) 200948. Expression values were normalised with 2 reference genes including 18SrRNA and GAPDH.

Western blot analysis

Western blot was performed as previously described42. Briefly, retinae were thawed and protein extraction was performed with RIPA buffer (Sigma, R0278) containing protease inhibitor (Roche, 04693159001), and QuantiPro BCA assay kit (Sigma-Aldrich, QPBCA) was used for protein quantification. Equal amounts of protein were loaded into each lane of NuPage Bis-Tris gels (Life Technologies, NP3023BOX), and transferred to a polyvinylidene difluoride membrane with semi-dry transfer system. The membranes were blocked with 5% BSA in TBST and the primary antibodies were incubated overnight at 4 °C. Primary antibodies include ZEB1 (Santa Cruz, sc-25388), ZEB2 (Abcam, ab25837), FLT1 (Abcam, ab32152), and VEGF (Abcam, ab1316). The horseradish peroxidase secondary antibody incubation was followed for 2–4 hours at room temperature. After ECL incubation, protein bands were visualised with GeneTool image scanning and densitometry measurement. The results were normalised with loading control of α/β tubulin (Cell Signalling, #2148).

In vivo gain and loss of function studies following intravitreal injections of miR-200b regulators

We performed intravitreal injections of miR-200b mimic (mirVana mimics, life technologies), miR-200b inhibitor (mirVana inhibitors, life technologies) to study the effects of miR-200b regulators on retinal vasculopathy 3 month after induced Müller cell disruption. A scrambled miRNA (mirVana negative control, life technologies) was injected in the same way as a control. A total of 18 mice were used for in vivo study: 8 mice received miR-200b mimic in one eye and the contralateral eye in each mouse received scrambled miRNA for comparison, with 2.8 μg/eye. Similarly, anti-miR-200b and scrambled RNA were injected in 10 mice. We used MaxSuppressorTM in vivo RNA-LANCErII (Bioo Scientific) as a miRNA mediator for efficient miRNA delivery. One week before intravitreal injection, we performed FFA to confirm the development of retinal vascular lesions after selective Müller cell disruption. The injected animals were re-examined for FFA to monitor changes in vascular lesions after intravitreal injections.

Immunofluorescence labelling

Immunofluorescence labelling was performed as previously described42,49. Briefly, eye cups were fixed with 4% paraformaldehyde in PBS for an hour at room temperature and incubated with 20% sucrose in PBS overnight at 4 °C. Then the eyecups were embedded in OCT, sectioned at 12 μm on Superfrost glass slides and stored at −20 °C until use. For fluorescent immunostaining, sections were thawed and washed with PBS 3 times for 5 minutes and blocked with 10% normal goat serum in PBS for 1 hour at room temperature. After washing with PBS, primary antibody incubation was followed for overnight at 4 °C. The primary antibodies used in this study were ZEB1 (Santa Cruz, sc-25388), ZEB2 (Abcam, ab25837), and cellular retinaldehyde binding protein (CRALBP, Abcam, ab15051). Isolectin B4 (IB4, Invitrogen I21413) was used to label blood vessels as previously described25. Secondary antibody incubation was performed the next day for 2–4 hours at room temperature followed by nuclear counterstaining with Hoechst. Sections were examined by confocal microscopy as described previously25,42.

Statistical analysis

Results were expressed as mean ± SEM. Data were analysed using unpaired Student t-test. A p value < 0.05 was regarded as statistically significant.

Additional Information

How to cite this article: Chung, S. H. et al. Differential expression of microRNAs in retinal vasculopathy caused by selective Müller cell disruption. Sci. Rep. 6, 28993; doi: 10.1038/srep28993 (2016).

Supplementary Material

Supplementary Information:


This study was supported by grants from Lowy Medical Research Institute, National Health and Medical Research Council (NHMRC, Australia; APP1028393) and Ophthalmic Research Institute of Australia. Mark Gillies is a fellow of Sydney Medical School Foundation and supported by a NHMRC Practitioner Fellowship.


Author Contributions W.S. and M.G. conceived the experiments; S.H.C., W.S., M.Y. and Y.W. conducted experiments; S.H.C. and W.S. analysed the results; S.H.C., M.G. and W.S. wrote the manuscript. The authors have no conflicting financial interests to declare.


  • Huntzinger E. & Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet 12, 99–110 (2011). [PubMed]
  • Fabian M. R., Sonenberg N. & Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 79, 351–379 (2010). [PubMed]
  • Xu S. microRNA expression in the eyes and their significance in relation to functions. Prog Retin Eye Res 28, 87–116 (2009). [PubMed]
  • Urbich C., Kuehbacher A. & Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovascular research 79, 581–588 (2008). [PubMed]
  • Fichtlscherer S. et al. . Circulating microRNAs in patients with coronary artery disease. Circulation research 107, 677–684 (2010). [PubMed]
  • Arora A., McKay G. J. & Simpson D. A. Prediction and verification of miRNA expression in human and rat retinas. Investigative ophthalmology & visual science 48, 3962–3967 (2007). [PubMed]
  • McArthur K., Feng B., Wu Y., Chen S. & Chakrabarti S. MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. Diabetes 60, 1314–1323 (2011). [PMC free article] [PubMed]
  • Wang S., Koster K. M., He Y. & Zhou Q. miRNAs as potential therapeutic targets for age-related macular degeneration. Future Med Chem 4, 277–287 (2012). [PMC free article] [PubMed]
  • Zhou Q. et al. . Regulation of angiogenesis and choroidal neovascularization by members of microRNA-23~27~24 clusters. Proc Natl Acad Sci USA 108, 8287–8292 (2011). [PubMed]
  • Fong D. S., Aiello L. P., Ferris F. L. 3rd & Klein R. Diabetic retinopathy. Diabetes care 27, 2540–2553 (2004). [PubMed]
  • Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. Arch Ophthalmol 115, 486–491 (1997). [PubMed]
  • Elman M. J. et al. . Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 118, 609–614 (2011). [PMC free article] [PubMed]
  • Ferris F. L. 3rd. How effective are treatments for diabetic retinopathy? Jama 269, 1290–1291 (1993). [PubMed]
  • Gillies M. C. et al. . Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 113, 1533–1538 (2006). [PubMed]
  • Michels R. G. Vitrectomy for complications of diabetic retinopathy. Arch Ophthalmol 96, 237–246 (1978). [PubMed]
  • Campochiaro P. A. Seeing the light: new insights into the molecular pathogenesis of retinal diseases. J Cell Physiol 213, 348–354 (2007). [PubMed]
  • Weidemann A. et al. . Astrocyte hypoxic response is essential for pathological but not developmental angiogenesis of the retina. Glia 58, 1177–1185 (2010). [PMC free article] [PubMed]
  • Kurihara T., Westenskow P. D., Bravo S., Aguilar E. & Friedlander M. Targeted deletion of Vegfa in adult mice induces vision loss. J Clin Invest 122, 4213–4217 (2012). [PMC free article] [PubMed]
  • Quaggin S. E. Turning a blind eye to anti-VEGF toxicities. J Clin Invest 122, 3849–3851 (2012). [PMC free article] [PubMed]
  • Gillies M. C. What we don’t know about avastin might hurt us. Arch Ophthalmol 124, 1478–1479 (2006). [PubMed]
  • Saint-Geniez M., Kurihara T., Sekiyama E., Maldonado A. E. & D’Amore P. A. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci USA 106, 18751–18756 (2009). [PubMed]
  • Saint-Geniez M. et al. . Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors. Plos one 3, e3554 (2008). [PMC free article] [PubMed]
  • Avery R. L. & Gordon G. M. Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema: A Systematic Review and Meta-analysis. JAMA ophthalmology 134, 21–29 (2016). [PubMed]
  • Bringmann A. et al. . Muller cells in the healthy and diseased retina. Prog Retin Eye Res 25, 397–424 (2006). [PubMed]
  • Shen W. et al. . Conditional Muller Cell Ablation Causes Independent Neuronal and Vascular Pathologies in a Novel Transgenic Model. The Journal of neuroscience: the official journal of the Society for Neuroscience 32, 15715–15727 (2012). [PMC free article] [PubMed]
  • Mizutani M., Gerhardinger C. & Lorenzi M. Muller cell changes in human diabetic retinopathy. Diabetes 47, 445–449 (1998). [PubMed]
  • Li Q. & Puro D. G. Diabetes-induced dysfunction of the glutamate transporter in retinal Muller cells. Investigative ophthalmology & visual science 43, 3109–3116 (2002). [PubMed]
  • Wu K. H., Madigan M. C., Billson F. A. & Penfold P. L. Differential expression of GFAP in early v late AMD: a quantitative analysis. The British journal of ophthalmology 87, 1159–1166 (2003). [PMC free article] [PubMed]
  • Powner M. B. et al. . Perifoveal muller cell depletion in a case of macular telangiectasia type 2. Ophthalmology 117, 2407–2416 (2010). [PMC free article] [PubMed]
  • Chung S. H. et al. . Profiling of microRNAs involved in retinal degeneration caused by selective Muller cell ablation. Plos one 10, e0118949 (2015). [PMC free article] [PubMed]
  • Shen W. et al. . Effect of glucocorticoids on neuronal and vascular pathology in a transgenic model of selective Muller cell ablation. Glia 62, 1110–1124 (2014). [PubMed]
  • Shen W., Zhu L., Lee S. R., Chung S. H. & Gillies M. C. Involvement of NT3 and P75(NTR) in photoreceptor degeneration following selective Muller cell ablation. Journal of neuroinflammation 10, 137 (2013). [PMC free article] [PubMed]
  • Choi Y. C., Yoon S., Jeong Y., Yoon J. & Baek K. Regulation of vascular endothelial growth factor signaling by miR-200b. Mol Cells 32, 77–82 (2011). [PMC free article] [PubMed]
  • Pecot C. V. et al. . Tumour angiogenesis regulation by the miR-200 family. Nat Commun 4, 2427 (2013). [PMC free article] [PubMed]
  • Zhao R., Qian L. & Jiang L. miRNA-dependent cross-talk between VEGF and Ang-2 in hypoxia-induced microvascular dysfunction. Biochemical and biophysical research communications 452, 428–435 (2014). [PubMed]
  • Takahashi Y., Chen Q., Rajala R. V. & Ma J. X. MicroRNA-184 modulates canonical Wnt signaling through the regulation of frizzled-7 expression in the retina with ischemia-induced neovascularization. FEBS letters 589, 1143–1149 (2015). [PMC free article] [PubMed]
  • Cai J. et al. . Roles of NFkappaB-miR-29s-MMP-2 circuitry in experimental choroidal neovascularization. Journal of neuroinflammation 11, 88 (2014). [PMC free article] [PubMed]
  • Li Y. X. et al. . miR-200a modulate HUVECs viability and migration. IUBMB Life 63, 553–559 (2011). [PubMed]
  • Xue X. et al. . MiR200-upregulated Vasohibin 2 promotes the malignant transformation of tumors by inducing epithelial-mesenchymal transition in hepatocellular carcinoma. Cell Commun Signal 12, 62 (2014). [PMC free article] [PubMed]
  • Chan Y. C., Khanna S., Roy S. & Sen C. K. miR-200b targets Ets-1 and is down-regulated by hypoxia to induce angiogenic response of endothelial cells. J Biol Chem 286, 2047–2056 (2011). [PMC free article] [PubMed]
  • Vandewalle C. et al. . SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions. Nucleic Acids Res 33, 6566–6578 (2005). [PMC free article] [PubMed]
  • Chung S. H. et al. . Differential Gene Expression Profiling after Conditional Muller Cell Ablation in a Novel Transgenic Model. Investigative ophthalmology & visual science (2013). [PubMed]
  • Brabletz S. & Brabletz T. The ZEB/miR-200 feedback loop–a motor of cellular plasticity in development and cancer? EMBO Rep 11, 670–677 (2010). [PubMed]
  • Bracken C. P. et al. . A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res 68, 7846–7854 (2008). [PubMed]
  • Korpal M., Lee E. S., Hu G. & Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 283, 14910–14914 (2008). [PMC free article] [PubMed]
  • Park S. M., Gaur A. B., Lengyel E. & Peter M. E. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 22, 894–907 (2008). [PubMed]
  • Renthal N. E. et al. . miR-200 family and targets, ZEB1 and ZEB2, modulate uterine quiescence and contractility during pregnancy and labor. Proc Natl Acad Sci USA 107, 20828–20833 (2010). [PubMed]
  • Pfaffl M. W., Horgan G. W. & Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30, e36 (2002). [PMC free article] [PubMed]
  • Chung S. H., Shen W. & Gillies M. C. Laser capture microdissection-directed profiling of glycolytic and mTOR pathways in areas of selectively ablated Muller cells in the murine retina. Investigative ophthalmology & visual science 54, 6578–6585 (2013). [PubMed]
  • Feng Y. et al. . A feedback circuit between miR-133 and the ERK1/2 pathway involving an exquisite mechanism for regulating myoblast proliferation and differentiation. Cell Death Dis 4, e934 (2013). [PMC free article] [PubMed]
  • Yin H. et al. . MicroRNA-133 controls brown adipose determination in skeletal muscle satellite cells by targeting Prdm16. Cell Metab 17, 210–224 (2013). [PMC free article] [PubMed]
  • Ahn J., Lee H., Jung C. H., Jeon T. I. & Ha T. Y. MicroRNA-146b promotes adipogenesis by suppressing the SIRT1-FOXO1 cascade. EMBO Mol Med 5, 1602–1612 (2013). [PMC free article] [PubMed]
  • Huszar J. & Payne C. J. miR-146a Influences Energy Metabolism, Cell Differentiation and Innate Immunity. Metabolomics 3 (2013).
  • Chang S. H. et al. . Antagonistic function of the RNA-binding protein HuR and miR-200b in post-transcriptional regulation of vascular endothelial growth factor-A expression and angiogenesis. J Biol Chem 288, 4908–4921 (2013). [PMC free article] [PubMed]
  • Dang L. T., Lawson N. D. & Fish J. E. MicroRNA control of vascular endothelial growth factor signaling output during vascular development. Arterioscler Thromb Vasc Biol 33, 193–200 (2013). [PMC free article] [PubMed]
  • Wainwright E. N. et al. . SOX9 regulates microRNA miR-202-5p/3p expression during mouse testis differentiation. Biol Reprod 89, 34 (2013). [PubMed]
  • Zhao Y. et al. . Decrease of miR-202-3p expression, a novel tumor suppressor, in gastric cancer. Plos one 8, e69756 (2013). [PMC free article] [PubMed]
  • Sun Z., Zhang T., Hong H., Liu Q. & Zhang H. miR-202 suppresses proliferation and induces apoptosis of osteosarcoma cells by downregulating Gli2. Mol Cell Biochem 397, 277–283 (2014). [PubMed]
  • Wang B. et al. . E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes 59, 1794–1802 (2010). [PMC free article] [PubMed]
  • Pichiorri F. et al. . Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 18, 367–381 (2010). [PMC free article] [PubMed]
  • Harraz M. M., Eacker S. M., Wang X., Dawson T. M. & Dawson V. L. MicroRNA-223 is neuroprotective by targeting glutamate receptors. Proc Natl Acad Sci USA 109, 18962–18967 (2012). [PubMed]
  • Lu H., Buchan R. J. & Cook S. A. MicroRNA-223 regulates Glut4 expression and cardiomyocyte glucose metabolism. Cardiovascular research 86, 410–420 (2010). [PubMed]

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group